News | Breast Imaging | May 16, 2022

Using U.S. guidelines, ProFound AI Risk found 14% of women studied who had a negative screen had almost 20 times higher risk of developing breast cancer in the next year than the general risk population

Using U.S. guidelines, ProFound AI Risk found 14% of women studied who had a negative screen had almost 20 times higher risk of developing breast cancer in the next year than the general risk population

May 16, 2022 —  iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that promising clinical research supporting ProFound AI® Risk for Digital Breast Tomosynthesis (DBT) – the world’s first clinical decision support tool that provides an accurate short-term breast cancer risk estimation based on age, breast density and mammographic features – was recently published in the peer-reviewed journal, Science Translational Medicine.[iv]  

In the study, which involved 154,200 women screened at four participating U.S. screening sites[v] using DBT from 2014-2019, researchers at the Karolinska Institutet in Stockholm, Sweden found ProFound AI Risk accurately determined women who were at a higher risk of developing breast cancer, with an area under the receiver operating characteristics curve (AUC) of 0.82iv, (95% CI 0.79-0.85). AUC is a standard performance measurement for examination procedures that incorporates sensitivity and specificity into a single metric of overall performance. This data supports iCAD’s internal research, which previously found ProFound AI Risk for DBT offers an AUC of 0.80 (95% CI 0.76, 0.83).[vi]  

“iCAD’s Breast AI Suite offers a complete portfolio of unrivaled breast cancer detection, density assessment, and short-term risk evaluation AI solutions, and we are pleased to see this compelling data further validate the clinical value of ProFound AI Risk, the latest addition to our breast AI portfolio,” said Stacey Stevens, President and CEO of iCAD, Inc. “Physicians have traditionally estimated breast cancer risk by examining the patient’s known risk factors, such as family history, but about 85% of breast cancers occur in women who have no family history of breast cancer.[vii] Additionally, traditional long-term risk models may not be as accurate at estimating a woman’s risk of developing breast cancer, as their average AUC is around 0.60.[viii] ProFound AI Risk offers a more individualized approach, as it includes a woman’s mammography images and focuses on one-to-two-years in the future, which provides critical information that can help clinicians personalize breast cancer screening regimens for patients based on their individual risk of developing cancer before or at their next screening.”

Established lifestyle-familial risk models, such as Tyrer-Cuzick and Gail, are currently used in the U.S. to identify women with a greater than 20% lifetime risk of developing breast cancer who could be offered breast magnetic resonance imaging (MRI) as a supplemental screening modality for breast cancer detection.iv However, these long-term risk models can result in a high number of false positives due to low-to-moderate discrimination performance.[ix] ProFound AI Risk complements traditional risk models and is easy for clinicians and medical facilities to adopt, as it only requires the images from a 2D or 3D mammogram, with no questionnaires, portals, or staff required to implement.

Using U.S. guidelines, the researchers determined that 14% of the women studied were at high risk after a negative or benign screening, with an almost 20-fold higher risk of developing breast cancer, compared to the general risk population. In this high-risk group, 76% of stage II or later cancers, 59% of stage 0, and 58% of stage 1 cancers were observed.

Researchers estimated if the 12% of women at highest risk had been offered supplemental screening based on the ProFound AI Risk for DBT model, up to 59% of the cancers could have potentially been detected, compared to 24% of the cancers using Tyrer-Cuzick. This corresponds to 2.4 times higher sensitivity than Tyrer-Cuzick.

“Our research showed that women who ProFound AI Risk determined to be at high risk were more likely to present with later stage tumors than early-stage cancers,” according to lead author of the study, Mikael Eriksson, PhD, Karolinska Institutet. “It is known that breast cancer survival is four and 12-fold worse for stage II and III cancers compared to stage 0 and I cancers in the first four years after diagnosis. Furthermore, the treatment cost for stage II and III cancers is more than twice that of stage 0 and I cancers in the first 24 months after diagnosis. ProFound AI Risk offers the potential to aid radiologists in refining personalizing screening recommendations and discussing risk with women, which could in turn influence their screening regimen compliance and potentially lead to earlier detection, reduced treatment costs and improved outcomes.”

Researchers also found ProFound AI Risk provided high accuracy in estimating future risk for invasive and in-situ cancers, screen detected and interval cancers, and in women with both dense and non-dense breasts.

“Earlier cancer detection can have a tremendous impact on women, from treatment to outcomes. And because women are often caretakers, improving outcomes in women’s health can also have cascading benefits for children, families, and communities,” added Stevens. “Only iCAD’s Breast AI suite provides clinicians unprecedented insights into each patient’s present and future, which offers the potential to transform the trajectory of a woman’s outcome and life.”

For more information: www.icadmed.com

References:

 

[i] Eriksson, M et al. A risk model for digital breast tomosynthesis to predict breast cancer and guide clinical care. Science Translational Medicine. 14 (644). 2022 May 11. Accessed via https://www.science.org/doi/10.1126/scitranslmed.abn3971.

[ii] Breastcancer.org. U.S. Breast Cancer Statistics. Accessed via https://www.breastcancer.org/symptoms/understand_bc/statistics.

[iii] Participating U.S. screening sites: Boca Raton Regional Hospital, Boca Raton, FL; Elizabeth Wende Breast Care, Rochester, NY; Larchmont, NJ; Zwanger-Pesiri Radiology, Lindenhurst, NY.

[iv] Eriksson, M et al. A risk model for digital breast tomosynthesis to predict breast cancer and guide clinical care. Science Translational Medicine. 14 (644). 2022 May 11. Accessed via https://www.science.org/doi/10.1126/scitranslmed.abn3971.

[v] Participating U.S. screening sites: Boca Raton Regional Hospital, Boca Raton, FL; Elizabeth Wende Breast Care, Rochester, NY; Larchmont, NJ; Zwanger-Pesiri Radiology, Lindenhurst, NY.

[vi] iCAD data on file. Variations per vendor and population may occur. ProFound AI Risk is a clinical decision support tool. Information is reviewed by the physician. All care decisions are up to physicians.

[vii] Breastcancer.org. U.S. Breast Cancer Statistics. Accessed via https://www.breastcancer.org/symptoms/understand_bc/statistics.

[viii] Eriksson M, Czene K, Strand F et al. Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening. Radiology. 2020 Sept 8. Accessed via https://doi.org/10.1148/radiol.2020201620.

[ix] M. H. Gail, R. M. Pfeiffer, Breast cancer risk model requirements for counseling, prevention, and screening. J. Natl. Cancer Inst. 110, 994–1002 (2018).

 


Related Content

Feature | Radiology Imaging | By Melinda Taschetta-Millane

It's been a fruitful month for itnonline.com! Here's a look at what ITN viewers found to be most interesting during the ...

Time June 01, 2023
arrow
News | Radiology Business

May 26, 2023 — HIMSS has appointed two technology executives at the helm as chair and vice chair of the HIMSS Board of ...

Time May 26, 2023
arrow
News | Computed Tomography (CT)

May 26, 2023 — GE HealthCare, a leading medical technology innovator, announced today its largest ever CT deal in the ...

Time May 26, 2023
arrow
News | Breast Density

May 25, 2023 — Researchers from the Mayo Clinic (Rochester, MN) and University of California, San Francisco confirmed ...

Time May 25, 2023
arrow
News | Breast Imaging

May 25, 2023 — GE HealthCare, a leader in breast cancer care technology and diagnostics, has today announced that NCCN ...

Time May 25, 2023
arrow
News | Ultrasound Women's Health

May 25, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR), deep ...

Time May 25, 2023
arrow
News | Artificial Intelligence

May 24, 2023 — Since the launch of ChatGPT in November 2022, the use of large language models (LLMs) powered by ...

Time May 24, 2023
arrow
News | Radiation Oncology

May 22, 2023 — Physicians and scientists from the UCLA Jonsson Comprehensive Cancer Center will discuss the latest ...

Time May 22, 2023
arrow
News | Mammography

May 22, 2023 — Incorrect advice by an AI-based decision support system could seriously impair the performance of ...

Time May 22, 2023
arrow
News | Artificial Intelligence

May 19, 2023 — The latest version of ChatGPT passed a radiology board-style exam, highlighting the potential of large ...

Time May 19, 2023
arrow
Subscribe Now